- Dr. Xiang-Qun (Sean) Xie has joined its Scientific Advisory Board
- Dr. Xie has over 30 years of experience in the fields of Genomics, Cancer Research
- Has multiple patents that have been licensed to BioTech and Pharmaceutical companies
LOS ANGELES, Jan. 24, 2019 (GLOBE NEWSWIRE) — Applied BioSciences Corp. (OTCQB: APPB), a diversified cannabinoid therapeutics company focused on the medical, bioceutical and pet health industries, announced that Dr. Xiang-Qun (Sean) Xie has joined its Scientific Advisory Board. Dr. Xie has over 30 years of experience in the fields of Genomics, Cancer Research and has multiple patents that have been licensed to BioTech and Pharmaceutical companies.
Although the health benefits of Cannabis and CBD are becoming well known, one of the challenges is the research and development of products for both the consumer, adult-use and pharmaceutical market. Many universities and doctors have been unable to research and access scientific data on the molecules and effect of phytocannabinoids.
The company continues to add professionals who are expert in relevant fields, such as scientific research and development, FDA procedures and medicine. These professionals will provide the company with an outstanding base of knowledge and experience to build on and advance the development of additional products. With the addition of several prominent scientists and physicians and their knowledge base, clinical trials, product development, and design procedures for submitting products to the FDA can be done in an expedited time frame.
Dr Xiang-Qun (Sean) Xie is an Associate Dean for Research Innovation at the School of Pharmacy and a Professor of Pharmaceutical Sciences/Drug Discovery Institute, and a PI of an integrated Medicinal Chemistry Biology laboratory of CompuGroup, BioGroup and ChemGroup at the University of Pittsburgh. He is a member of the Science Advisory Board to the US Food and Drug Administration (FDA). He is a Founding Director of Computational Chemical Genomics Screening Center, and a Director/PI of NIH National Center of Excellence for CDAR. He holds joint positions at Dept of Computational Biology and Dept of Structural Biology, and Pitt Cancer Institute MT/DD Program. He is an Editorial Advisory Board member for the AAPS Journal and American Journal.
“I have been impressed with the Applied BioSciences team and their experience in the Cannabis and CBD space and use of analytical science and best practices of testing in the manufacturing of products. I look forward to bringing my own background in research and development of compounds, patents to help further commercialize products that help to treat and provide the natural healing and properties of both Cannabis and CBD,†commented Dr Xie.
“Applied BioSciences continues to develop, produce and commercialize products for the consumer, medical and the over-the-counter market to treat ailments, as well as for general health and wellness. Research and scientific formulation are at the heart of everything we do. As the company continues to expand our product lines, it is important to expand our scientific and research development pipeline and partner with leaders in the space. We will now be able to expand the addressable market of our products and focus on additional scientific research, clinical data and patents to expand our product portfolio,†commented Chris Bridges, President of Applied BioSciences Corp.
Applied BioSciences products use base ingredients that are USDA Organic and non-GMO. Offering Vegan, sugar-free, 99% Pure CBD Isolate infused. The products are formulated with CBD extracted from pesticide-free, organically grown, domestically produced, High-CBD Industrial Hemp. Lab-tested and guaranteed Pesticide and Chemical-free. Our proprietary blends also contain USDA certified organic botanicals, herbals and essential oils to provide synergy with other healing elements found in nature.
About Applied BioSciences Corp.
Applied BioSciences Corp. (www.appliedbiocorp.com),
is a diversified company focused on multiple areas of the medical,
bioceutical and pet health industry. As a leading company in the CBD and
Pet health space, the company is currently shipping to the majority of
US states as well as to 5 International countries. The company is
focused on select investment, consumer brands, and partnership
opportunities in the recreational, health and wellness, nutraceutical,
and media industries.
About Trace Analytics Inc.
Trace
Analytics Inc. is a leading cannabis science and technology company
with significant footprints in lab testing, research and development and
licensing. Trace Analytics was started by a group of scientists who
specialized in analytical chemistry, genetics and molecular biology.
The focus of the team is to ensure compliance with public safety
standards and end user safety. Trace Analytics is in the process of
expanding throughout the United States, and globally. With the goal of
helping the rest of the world adopt “best practices” in cannabis and
hemp testing, the company also provides expert consulting services to
legislators and regulators in many countries, states and municipalities
around the world. For more information, please visit:
http://traceanalytics.com
Contact
Email: [email protected] or [email protected]
To be added to the Applied BioSciences email distribution list, please email [email protected] with APPB in the subject line.
Official Website:www.appliedbiocorp.com / www.traceanalytics.com
Brands:
www.remedishop.com
www.herbalpet.com
www.canagel.com
Follow us:
Facebook @remedicbd & @HerbalPetMeds
Instagram @remedishop & @herbal_pet
Twitter @remedishop & @herbal_pet
